Joanne Khabsa

Joanne Khabsa

Auto-generated profile, based on publicly available information

Joanne Khabsa

Clinical Research Institute American University of Beirut Beirut Lebanon

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in BMJ Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
ODOmar Dewidar
Omar Dewidar
TLTamara Lotfi
Tamara Lotfi
MLMiranda W Langendam
Miranda W Langendam
EPElena Parmelli
Elena Parmelli
ZPZuleika Saz Parkinson
Zuleika Saz Parkinson
HSHolger J Schünemann
Holger J Schünemann
An evidence-based approach is considered the gold standard for health decision-making. Sometimes, a guideline panel might judge the certainty that the desirable effects of an intervention clearly outweigh its undesirable effects as high, but the body of supportive evidence is indirect. In such cases, the application of the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach for grading the strength of recommendations is inappropriate. Instead, the GRADE Working Group has recommended developing ungraded best or good practice statement (GPS) and developed guidance under which circumsances they would be appropriate.Through an evaluation of COVID-1- related recommendations on the eCOVID Recommendation Map (COVID-19.recmap.org), we found that recommendations qualifying a GPS were widespread. However, guideline developers failed to label them as GPS or transparently report justifications for their development. We identified ways to improve and facilitate the operationalisation and implementation of the GRADE guidance for GPS.Herein, we propose a structured process for the development of GPSs that includes applying a sequential order for the GRADE guidance for developing GPS. This operationalisation considers relevant evidence-to-decision criteria when assessing the net consequences of implementing the statement, and reporting information supporting judgments for each criterion. We also propose a standardised table to facilitate the identification of GPS and reporting of their development. This operationalised guidance, if endorsed by guideline developers, may palliate some of the shortcomings identified. Our proposal may also inform future updates of the GRADE guidance for GPS.

29 October 2024 in Cochrane Evidence Synthesis and Methods
Verified
Journal Article
Open access
EAElie Akl
Elie Akl
JKJoanne Khabsa
Joanne Khabsa
JPJennifer Petkovic
Jennifer Petkovic
OMOlivia Magwood
Olivia Magwood
LLLyubov Lytvyn
Lyubov Lytvyn
TCThomas W. Concannon
Thomas W. Concannon
Background: Given the colonial connotations of the term “stakeholder”, its continued use may be perceived as disrespectful to Indigenous Peoples. While several groups have introduced alternative terms, each has its own limitations. The objective of this article is to introduce “interest‐holders” as an alternative term to “stakeholders” and describe the discussions underpinning the adoption of the new term by the MuSE Consortium.Methods: The MuSE Consortium is an international network of over 160 individuals with interest and expertise in different aspects relevant to engagement in research. Members of MuSE explored alternative terms and considered their respective merits and limitations. The deliberations considered the literature on the topic and the results of two consultations with the wider MuSE membership on the alternative terms.Results: We define “interest‐holders” as groups with legitimate interests in the health issue under consideration. The interests arise and draw their legitimacy from the fact that people from these groups are responsible for or affected by health‐related decisions that can be informed by research evidence.Conclusion: As groups other than the MuSE Consortium have started to adopt “interest‐holders,” we hope its use will reduce confusion related to the multitude of terms used and convey the intended meaning without any negative connotations.

4 August 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
HSHolger J. Schünemann
Holger J. Schünemann
JKJoanne Khabsa
Joanne Khabsa
KSKarla Solo
Karla Solo
AKAssem M. Khamis
Assem M. Khamis
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
EAElie A. Akl
Elie A. Akl
This living systematic review examines evidence about the benefits and harms of alternative noninvasive and invasive ventilation strategies in acute hypoxic respiratory failure in patients infected... Background: Mechanical ventilation is used to treat respiratory failure in coronavirus disease 2019 (COVID-19). Purpose: To review multiple streams of evidence regarding the benefits and harms of v...

14 May 2020 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
SYSally Yaacoub
Sally Yaacoub
HSHolger J Schünemann
Holger J Schünemann
JKJoanne Khabsa
Joanne Khabsa
AEAmena El-Harakeh
Amena El-Harakeh
AKAssem M Khamis
Assem M Khamis
EAElie Akl
Elie Akl
Introduction Proper strategies to minimise the risk of infection in individuals handling the bodies of deceased persons infected with 2019 novel coronavirus (2019-nCoV) are urgently needed. The objective of this study was to systematically review the literature to scope and assess the effects of specific strategies for the management of the bodies. Methods We searched five general, three Chinese and four coronavirus disease (COVID-19)–specific electronic databases. We searched registries of clinical trials, websites of governmental and other relevant organisations, reference lists of the included papers and relevant systematic reviews, and Epistemonikos for relevant systematic reviews. We included guidance documents providing practical advice on the handling of bodies of deceased persons with suspected or confirmed COVID-19. Then, we sought primary evidence of any study design reporting on the efficacy and safety of the identified strategies in coronaviruses. We included evidence relevant to contextual factors (ie, acceptability). A single reviewer extracted data using a pilot-tested form and graded the certainty of the evidence using the GRADE approach. A second reviewer verified the data and assessments. Results We identified one study proposing an uncommon strategy for autopsies for patients with severe acute respiratory syndrome. The study provided very low-certainty evidence that it reduced the risk of transmission. We identified 23 guidance documents providing practical advice on the steps of handling the bodies: preparation, packing, and others and advice related to both the handling of the dead bodies and the use of personal protective equipment by individuals handling them. We did not identify COVID-19 evidence relevant to any of these steps. Conclusion While a substantive number of guidance documents propose specific strategies, we identified no study providing direct evidence for the effects of any of those strategies. While this review highlights major research gaps, it allows interested entities to build their own guidance.

1 June 2024 in Annals of Internal Medicine
Verified
Journal Article
Open access
YXYangqin Xun
Yangqin Xun
JEJanne Estill
Janne Estill
JKJoanne Khabsa
Joanne Khabsa
IFIvan Florez
Ivan Florez
Gordon H. GuyattGordon H. Guyatt
Gordon H. Guyatt
RGRight-Coi&F Working Groups
Right-Coi&F Working Groups
Conflicts of interest (COIs) of contributors to a guideline project and the funding of that project can influence the development of the guideline. Comprehensive reporting of information on COIs and funding is essential for the transparency and credibility of guidelines. To develop an extension of the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement for the reporting of COIs and funding in policy documents of guideline organizations and in guidelines: the RIGHT-COI&F checklist. The recommendations of the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network were followed. The process consisted of registration of the project and setting up working groups, generation of the initial list of items, achieving consensus on the items, and formulating and testing the final checklist. International collaboration. 44 experts. Consensus on checklist items. The checklist contains 27 items: 18 about the COIs of contributors and 9 about the funding of the guideline project. Of the 27 items, 16 are labeled as policy related because they address the reporting of COI and funding policies that apply across an organization's guideline projects. These items should be described ideally in the organization's policy documents, otherwise in the specific guideline. The remaining 11 items are labeled as implementation related and they address the reporting of COIs and funding of the specific guideline. The RIGHT-COI&F checklist requires testing in real-life use. The RIGHT-COI&F checklist can be used to guide the reporting of COIs and funding in guideline development and to assess the completeness of reporting in published guidelines and policy documents. The Fundamental Research Funds for the Central Universities of China.

19 December 2019 in Health Expectations
Verified
Journal Article
Open access
PDF file
JKJoanne Khabsa
Joanne Khabsa
ASAline Semaan
Aline Semaan
AEAmena El‐Harakeh
Amena El‐Harakeh
AKAssem M. Khamis
Assem M. Khamis
SOSerena Obeid
Serena Obeid
EAElie Akl
Elie Akl
Background: Patients and consumers are increasingly engaged in health policymaking, research and drug regulation. Having financial relationships with the health industry creates situations of conflicts of interest (COI) and might compromise their meaningful and unbiased participation.Objective: To synthesize available evidence on the financial relationships between the health industry and patient and consumer representatives and their organizations.Methods: We systematically searched MEDLINE and EMBASE. We selected studies and abstracted data in duplicate and independently. We reported on outcomes related to financial relationships of individuals with, and/or funding of organizations by the health industry.Results: We identified a total of 14 510 unique citations, of which 24 reports of 23 studies were eligible. Three studies (13%) addressed the financial relationship of patient and consumer representatives with the health industry. Of these, two examined the proportion of public speakers in drug regulatory processes who have financial relationships; the proportions in the two studies were 25% and 19% respectively. Twenty studies (87%) addressed funding of patient and consumer organizations. The median proportion of organizations that reported funding from the health industry was 62% (IQR: 34%‐69%) in questionnaire surveys, and 75% (IQR: 58%‐85%) in surveys of their websites. Among organizations for which there was evidence of industry funding, a median proportion of 29% (IQR: 27%‐44%) acknowledged on their websites receiving that funding.Conclusion: Financial relationships between the health industry and patient and consumer representatives and their organizations are common and may not be disclosed. Stricter regulation on disclosure and management is needed.